(Q36505106)

14 August 2017

0 references

1 reference

title

Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers (English)

1 reference

14 August 2017

1 reference

1

Jaffer Ajani

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

107

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

221-231

1 reference

Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

The attitudes of cancer patients and their families toward the disclosure of terminal illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Palliative chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Chemotherapy in gastric cancer: a review and updated meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21986

7 January 2021

Identifiers

DOI

10.1002/CNCR.21986

1 reference

14 August 2017

1 reference